Market Research Logo

Global MRSA Drugs Market 2016-2020

About Methicillin-Resistant Staphylococcus aureus (MRSA)

MRSA is an infection of the skin that occurs mostly in hospitals and healthcare facilities. It is treated with commonly-used antibiotics and usually spreads from person to person by direct skin-to-skin contact. Physicians often find MRSA harder to treat than most other strains of Staphylococcus aureus because it is sometimes resistant to commonly-used antibiotics such as methicillin.

Technavio’s analysts forecast the global MRSA drugs market to grow at a CAGR of 1.34% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global MRSA drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generic drugs used to treat and prevent MRSA infections.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global MRSA Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Allergan
  • Merck & Co.
  • Pfizer
  • Theravance Biopharma
Other prominent vendors
  • Absynth Biologics
  • AmpliPhi Biosciences Corporation
  • AstraZeneca
  • Basilea Pharmaceutica
  • Baxter International
  • Cellceutix
  • Cempra Inc.
  • CrystalGenomics
  • Debiopharm Group
  • Galapagos NV
  • GSK
  • KYORIN Pharmaceutical
  • Lytix Biopharma
  • Melinta Therapeutics
  • Nabriva Therapeutics
  • NovaDigm Therapeutics
  • Paratek Pharmaceuticals
  • R-Pharm
  • Savara Pharmaceuticals
  • Sealife Pharma
  • Sequella Inc.
  • The Medicines Company
  • XBiotech
Market driver
  • Special regulatory designations
  • For a full, detailed list, view our report
Market challenge
  • Development of drug-resistant strains
  • For a full, detailed list, view our report
Market trend
  • Strategic alliances and M&A
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global MRSA Drugs Market 2016-2020

Technavio recognizes the following companies as the key players in the global MRSA drugs market: Allergan, Merck, Pfizer, and Theravance.

Other Prominent Vendors in the market are: Absynth Biologics, AmpliPhi Biosciences, AstraZeneca, Basilea Pharmaceutica , Baxter International, Cellceutix, Cempra, CrystalGenomics, Debiopharm, Galapagos NV, GSK, KYORIN Pharmaceutical, Lytix Biopharma, Melinta Therapeutics, Nabriva Therapeutics, NovaDigm Therapeutics, Paratek Pharmaceuticals, R-Pharm, Savara Pharmaceuticals, Sealife Pharma, Sequella, The Medicines Company, and XBiotech.

Commenting on the report, an analyst from Technavio’s team said: “Strategic alliances and M&A will be the key trend for market growth. Strategic alliances help co-develop and commercialize drugs. These agreements enable the use of technical expertise from both companies, as well as the use of regulatory and development experience gained by one company for the support of pipeline candidates of another company. They ensure the in-flow of adequate funds from both the companies, reducing liability costs for individual companies in case of failures. M&A are usually intended to increase the market penetration of the acquirer or enhance the product portfolio of the parent company.”

According to the report, growing awareness of diseases will be a key driver for market growth because it has increased the use of drugs. October is celebrated as World MRSA Awareness Month. European Antibiotic Awareness Day was celebrated on November 18, 2014 to raise awareness of antibiotic resistance and promote judicious use of antibiotics. The US Department of Health and Human Services developed Healthy People 2020, which aims to prevent and treat infectious diseases. Other awareness programs include World Hand Hygiene Day on May 5, National Infection Control Week in the third week of October, World Pneumonia Day on November 12, and Antibiotic Awareness Week in the third week in November. These programs help increase the treatment seeking population, thus driving the market.

Further, the report states that patent expiries and generic penetration will be the challenges for by the market. The loss of patent exclusivity of branded drugs results in the development of generic formulations, which are similar in quality, dosage form, strength, and efficacy, but less costly. There has been a significant increase in generic competition because of the patent expiries of major MRSA drugs. In the emerging markets of Asia, Africa, and South America, the increase in generic competition is leading to downward pricing pressures, which challenges market expansion.



Companies Mentioned

Allergan, Merck, Pfizer, Theravance, Absynth Biologics, AmpliPhi Biosciences, AstraZeneca, Basilea Pharmaceutica , Baxter International, Cellceutix, Cempra, CrystalGenomics, Debiopharm, Galapagos NV, GSK, KYORIN Pharmaceutical, Lytix Biopharma, Melinta Therapeutics, Nabriva Therapeutics, NovaDigm Therapeutics, Paratek Pharmaceuticals, R-Pharm, Savara Pharmaceuticals, Sealife Pharma, Sequella, The Medicines Company, XBiotech.

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
      • Table Percentage of MRSA infections among Staphylococcus infections in US 2015
      • Table Percentage of MRSA infections in US based on type 2015
      • Table Sites of Staphylococcus infections
  • Key buying criteria
    • Table Key buying criteria for MRSA drugs
  • Antibacterial: Overview
    • Introduction
    • MOA
      • Table MOA of antibacterial drugs
    • General principles for use of antibiotics
      • Table General principles involved in use of antibiotics
    • Clinical uses
  • Antimicrobial resistance
    • Table Causes of AMR
    • Sources of spread of resistant organisms
      • Table Sources of spread of resistant organisms
      • Table Estimated deaths per year caused by AMR in 2050
    • Initiatives to improve antibiotic innovation
      • Table Initiatives improving antibiotic innovation
    • Surveillance systems for antibiotic resistance
      • Table Surveillance systems of various countries
  • Legislation relating to antibiotics use in US
    • Table Legislation relating to antibiotics use in US
  • Pipeline analysis
    • Table Pipeline portfolio: Global MRSA drugs market
    • Solithromycin
    • TD-1792
    • Baxdela
    • Taksta
  • Market landscape
    • Global antibacterial drugs market
      • Table Global antibacterial drugs market 2015-2020 ($ billions)
    • Global MRSA drugs market
      • Table Market share of global MRSA drugs in global pharmaceutical market 2015
      • Table Global MRSA drugs market 2015-2020 ($ billions)
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by drug class
    • Tetracycline
    • Folate antagonists
    • Cephalosporin
      • Table Cephalosporin segmentation by generation of drugs
    • Lipopeptide
    • Oxazolidinone
    • Lipoglycopeptide
      • Table Global MRSA drugs market segmentation based on volume 2015
  • Market segmentation by drug origin
    • Table Global MRSA drugs market segmentation by drug origin
    • Semisynthetic drugs
    • Synthetic drugs
  • Market segmentation by MOA
    • Bacteriostatic
    • Bactericidal
  • Geographical segmentation
    • Global MRSA drugs market by geographical segmentation 2015-2020
      • Table Global MRSA drugs market segmentation by geography 2015
      • Table Global MRSA drugs market revenue by geography 2015-2020 ($ millions)
      • Table Percentage share of global MRSA drugs market by geography 2015-2020
    • MRSA drugs market in Americas
      • Table MRSA drugs market in Americas 2015-2020 ($ billions)
      • Table Percentage share of MRSA drugs market in US 2015
    • MRSA drugs market in EMEA
      • Table MRSA drugs market in EMEA 2015-2020 ($ millions)
    • MRSA drugs market in APAC
      • Table MRSA drugs market in APAC 2015-2020 ($ millions)
      • Table Global MRSA drugs market: YoY growth and revenue based on geography 2015-2020
  • Market drivers
    • Special regulatory designations
    • Increasing prevalence of infections
      • Table Percentage of MRSA infections 2014
    • Growing awareness of diseases
    • Rise in older population
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Development of drug-resistant strains
      • Table Antibiotic-resistant strains of Staphylococcus according to period of development of resistance
      • Table Ranking for top ten countries based on antibiotic consumption in livestock 2015
    • Patent expiries and generic penetration
    • Decreased investments in research activities
      • Table Antibacterial drug approvals by FDA and EMA
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Strategic alliances and M&A
    • Patient assistance programs
    • Increased funding for antibiotic research
  • Vendor landscape
    • Competitive scenario
    • Key vendor profiles
      • Allergan
        • Table Allergan: Key takeaways
    • Merck
      • Table Merck: YoY revenue and growth rate of Cubicin 2013-2015 ($ billion)
      • Table Merck: Key takeaways
    • Pfizer
      • Table Pfizer: YoY revenue and growth rate of Zyvox 2013-2015 ($ millions)
      • Table Pfizer: YoY revenue and growth rate of Tygacil 2013-2015 ($ millions)
      • Table Pfizer: Key takeaways
    • Theravance
      • Table Theravance Biopharma: YoY revenue comparison of Vibativ 2014-2015 ($ millions)
      • Table Theravance: Key takeaways
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report